Koninklijke Philips Continues To Expects 3-5% Comparable Sales Growth And Adjusted EBITA Margin Of 11-11.5%; Sees Free Cash Flow Of EUR 0.9B-1.1B
Koninklijke Philips Continues To Expects 3-5% Comparable Sales Growth And Adjusted EBITA Margin Of 11-11.5%; Sees Free Cash Flow Of EUR 0.9B-1.1B
Outlook
外表
Philips reiterates its confidence in delivering the 2025 plan, acknowledging that uncertainties remain. For the full year 2024, Philips continues to expect 3-5% comparable sales growth and an Adjusted EBITA margin of 11-11.5%.
飞利浦重申了对实现2025年计划的信心，承认不确定性仍然存在。飞利浦继续预计，2024年全年可比销售增长3-5％，调整后的息税折旧摊销前利润率为11-11.5％。
The expected free cash flow is now increased to EUR 0.9-1.1 billion in 2024, including the receipt from insurers for the Respironics product liability claims and the remaining payment related to the economic loss settlement.
现在，预期的自由现金流将在2024年增加到9-11亿欧元，其中包括保险公司为Respironics产品责任索赔收款以及与经济损失和解相关的剩余款项。
The personal injury and medical monitoring litigation settlement payment is expected in 2025. The outlook excludes the potential impact of other previously disclosed Philips Respironics-related legal proceedings, including the investigation by the US Department of Justice.
人身伤害和医疗监督诉讼和解金预计将在2025年支付。该展望不包括先前披露的其他飞利浦Respironics相关法律诉讼的潜在影响，包括美国司法部的调查。